indomethacin has been researched along with Fetal Death in 32 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Fetal Death: Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.
Excerpt | Relevance | Reference |
---|---|---|
"Long-term indomethacin treatment during pregnancy may lead to the development of renal failure and irreversible renal damage with cystic dilatation of developing nephrons in an exposed fetus." | 7.69 | Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. ( Bavoux, F; Carlus, C; Delezoide, AL; Gubler, MC; Narcy, F; van der Heijden, BJ, 1994) |
"A case of severe fetal congestive heart failure due to occlusion of the ductus arteriosus in a mother treated with indomethacin for polyhydramnios and premature contractions is described." | 7.69 | In utero congestive heart failure due to maternal indomethacin treatment for polyhydramnios and premature labour in a fetus with antenatal closure of the foramen ovale. ( Achiron, R; Berant, M; Hegesh, J; Kidron, D; Lipitz, S; Rotstein, Z, 1996) |
"Eight gravidas with symptomatic polyhydramnios were managed with maternal indomethacin therapy." | 7.68 | Indomethacin therapy in the treatment of symptomatic polyhydramnios. ( Kirshon, B; Mari, G; Moise, KJ, 1990) |
"When Indomethacin in a dosage of 175 mg/day was used to treat threatened premature labour more than 70% of cases carried on until 37 weeks." | 6.37 | [Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients]. ( Barrat, J; Bouillie, J; Boyer, F; Keskes, J; Marpeau, L; Pigné, A; Vincenti, O, 1988) |
"To investigate the effect of cervical application of nonselective and selective inhibitors of nitric oxide synthases--N-nitro-L-arginine methyl ester, L-N-iminoethyl-lysine, and aminoguanidine--as well as inhibitors of cyclooxygenases--indomethacin, and nimesulide--on timing of delivery and fetal death and disease in pregnant rats." | 3.71 | The effects of cervical application of inhibitors of inducible nitric oxide synthase, cyclooxygenase-1, and cyclooxygenase-2 on delivery in rats. ( Bukowski, R; Garfield, RE; McKay, L; Saade, GR; Shi, SQ, 2001) |
"Long-term indomethacin treatment during pregnancy may lead to the development of renal failure and irreversible renal damage with cystic dilatation of developing nephrons in an exposed fetus." | 3.69 | Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin. ( Bavoux, F; Carlus, C; Delezoide, AL; Gubler, MC; Narcy, F; van der Heijden, BJ, 1994) |
"A case of severe fetal congestive heart failure due to occlusion of the ductus arteriosus in a mother treated with indomethacin for polyhydramnios and premature contractions is described." | 3.69 | In utero congestive heart failure due to maternal indomethacin treatment for polyhydramnios and premature labour in a fetus with antenatal closure of the foramen ovale. ( Achiron, R; Berant, M; Hegesh, J; Kidron, D; Lipitz, S; Rotstein, Z, 1996) |
"Eight gravidas with symptomatic polyhydramnios were managed with maternal indomethacin therapy." | 3.68 | Indomethacin therapy in the treatment of symptomatic polyhydramnios. ( Kirshon, B; Mari, G; Moise, KJ, 1990) |
"Indomethacin was significantly more effective than placebo in inhibition of premature labor during a 24-hour course of therapy, with treatment failure during therapy occurring in only one of 15 indomethacin-treated patients compared to nine of 15 placebo-treated patients (p less than 0." | 2.65 | The inhibition of premature labor with indomethacin. ( Blake, DA; Dubin, NH; Egner, PG; Kumor, KM; Niebyl, JR; Robinson, JC; White, RD, 1980) |
" The first treatment consisted of the administration of ritodrine and a placebo; in the second, ritodrine was combined with indomethacin." | 2.64 | A study of indomethacin combined with ritodrine in threatened preterm labor. ( Cañas, E; Cararach, V; Edo, A; Gamissans, O; Puerto, B; Ribas, J, 1978) |
"When Indomethacin in a dosage of 175 mg/day was used to treat threatened premature labour more than 70% of cases carried on until 37 weeks." | 2.37 | [Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients]. ( Barrat, J; Bouillie, J; Boyer, F; Keskes, J; Marpeau, L; Pigné, A; Vincenti, O, 1988) |
"When pregnancy is continued after death of one fetus in monochorionic twin pregnancy, the surviving fetus sometimes exhibits intrauterine death or brain damage." | 1.30 | Hysterotomy and selective delivery of an intrauterine dead fetus to prevent intrauterine death or brain damage of the surviving fetus in monochorionic twin pregnancy. ( Ito, T; Kadowaki, K; Makio, A; Nagata, N; Takahashi, H; Terakawa, N, 1997) |
"Pretreatment with indomethacin significantly decreased the proportion of fetal death from 83% to < 25% in mice injected with 10 micrograms of LPS." | 1.29 | Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. ( Branch, DW; Dudley, DJ; Edwin, SS; Mitchell, MD; Silver, RM; Simmons, DL; Trautman, MS, 1995) |
"In the three cases of severe twin-to-twin transfusion syndrome no reduction of amniotic fluid in either sac was demonstrated." | 1.29 | Indomethacin in severe twin-to-twin transfusion syndrome. ( Cetrulo, CL; D'Alton, ME; Dilillo, L; Jones, JM; Sbarra, AJ, 1993) |
"Indomethacin (Id) treatment of rabbits at the time of implantation resulted in a significant reduction in the number of viable embryos as well as significant reduction in plasma progesterone concentrations." | 1.27 | Treatment with prostaglandins reduces the antifertility effect of indomethacin in rabbits. ( el-Banna, AA, 1986) |
"A case of hydrops fetalis with intra-uterine death after premature closure of the ductus arteriosus because of inhibition of premature labour by the administration of indomethacin is presented." | 1.27 | Premature closure of the ductus arteriosus causing intra-uterine death. A case report. ( Coetzee, MJ; Franszen, S; Truter, PJ; van der Merwe, JV, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 21 (65.63) | 18.7374 |
1990's | 9 (28.13) | 18.2507 |
2000's | 2 (6.25) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Parfenova, H | 1 |
Levine, V | 1 |
Gunther, WM | 1 |
Pourcyrous, M | 1 |
Leffler, CW | 1 |
Skosyreva, AM | 1 |
Khachapuridze, NV | 1 |
Golovanova, IV | 1 |
Harrison, MR | 1 |
Anderson, J | 1 |
Rosen, MA | 1 |
Ross, NA | 1 |
Hendrickx, AG | 1 |
Nara, BS | 1 |
First, NL | 1 |
Niebyl, JR | 1 |
Blake, DA | 1 |
White, RD | 1 |
Kumor, KM | 1 |
Dubin, NH | 1 |
Robinson, JC | 1 |
Egner, PG | 1 |
Itskovitz, J | 1 |
Abramovici, H | 1 |
Brandes, JM | 1 |
Harris, WH | 1 |
Marks, TA | 1 |
Tracy, DE | 1 |
Silver, RM | 2 |
Edwin, SS | 2 |
Trautman, MS | 1 |
Simmons, DL | 1 |
Branch, DW | 2 |
Dudley, DJ | 2 |
Mitchell, MD | 2 |
van der Heijden, BJ | 1 |
Carlus, C | 1 |
Narcy, F | 1 |
Bavoux, F | 1 |
Delezoide, AL | 1 |
Gubler, MC | 1 |
Jones, JM | 1 |
Sbarra, AJ | 1 |
Dilillo, L | 1 |
Cetrulo, CL | 1 |
D'Alton, ME | 1 |
Achiron, R | 1 |
Lipitz, S | 1 |
Kidron, D | 1 |
Berant, M | 1 |
Hegesh, J | 1 |
Rotstein, Z | 1 |
Umar, F | 1 |
Ito, T | 1 |
Kadowaki, K | 1 |
Takahashi, H | 1 |
Nagata, N | 1 |
Makio, A | 1 |
Terakawa, N | 1 |
Bukowski, R | 1 |
McKay, L | 1 |
Shi, SQ | 1 |
Saade, GR | 1 |
Garfield, RE | 1 |
Sharpe, GL | 1 |
Krous, H | 1 |
Altshuler, G | 1 |
Karim, SM | 1 |
Gamissans, O | 1 |
Cañas, E | 1 |
Cararach, V | 1 |
Ribas, J | 1 |
Puerto, B | 1 |
Edo, A | 1 |
Kamel, S | 1 |
Wood, GW | 1 |
Kirshon, B | 1 |
Mari, G | 1 |
Moise, KJ | 1 |
Guthrie, HD | 1 |
el-Banna, AA | 1 |
Marpeau, L | 1 |
Keskes, J | 1 |
Vincenti, O | 1 |
Boyer, F | 1 |
Bouillie, J | 1 |
Pigné, A | 1 |
Barrat, J | 1 |
Randall, CL | 1 |
Anton, RF | 1 |
Becker, HC | 1 |
Truter, PJ | 1 |
Franszen, S | 1 |
van der Merwe, JV | 1 |
Coetzee, MJ | 1 |
Persaud, TV | 3 |
Moore, KL | 2 |
Aiken, JW | 1 |
Chester, R | 1 |
Dukes, M | 1 |
Slater, SR | 1 |
Walpole, AL | 1 |
Skarnes, RC | 2 |
Harper, MJ | 2 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Vaginal Indomethacin Versus Oral Nifedipine for Preterm Labor; a Randomized Controlled Trial[NCT04404686] | Phase 2/Phase 3 | 300 participants (Anticipated) | Interventional | 2020-10-31 | Not yet recruiting | ||
Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-08-01 | Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.) | ||
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
3 reviews available for indomethacin and Fetal Death
Article | Year |
---|---|
On the use of blockers of prostaglandin synthesis in the control of labor.
Topics: Animals; Aspirin; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Indome | 1978 |
Control of time of parturition in pigs.
Topics: Adrenergic beta-Antagonists; Adrenocorticotropic Hormone; Animal Husbandry; Animals; Dinoprost; Fema | 1985 |
[Value and dangers of indomethacin used in pregnancy. Apropos of 304 treated patients].
Topics: Abortion, Threatened; Acute Kidney Injury; Ductus Arteriosus, Patent; Female; Fetal Death; Fetus; Hu | 1988 |
3 trials available for indomethacin and Fetal Death
Article | Year |
---|---|
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
The inhibition of premature labor with indomethacin.
Topics: Dinoprost; Double-Blind Method; Drug Evaluation; Estradiol; Female; Fetal Blood; Fetal Death; Humans | 1980 |
On the use of blockers of prostaglandin synthesis in the control of labor.
Topics: Animals; Aspirin; Clinical Trials as Topic; Female; Fetal Death; Fetus; Hemodynamics; Humans; Indome | 1978 |
A study of indomethacin combined with ritodrine in threatened preterm labor.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Fetal Death | 1978 |
27 other studies available for indomethacin and Fetal Death
Article | Year |
---|---|
COX-1 and COX-2 contributions to basal and IL-1 beta-stimulated prostanoid synthesis in human neonatal cerebral microvascular endothelial cells.
Topics: Animals; Cells, Cultured; Cerebrovascular Circulation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyg | 2002 |
[Action of indomethacin on fetal development].
Topics: Animals; Dose-Response Relationship, Drug; Embryo Implantation; Female; Fetal Death; Fetus; Indometh | 1984 |
Fetal surgery in the primate I. Anesthetic, surgical, and tocolytic management to maximize fetal-neonatal survival.
Topics: Anesthetics; Animals; Female; Fetal Death; Fetal Viability; Fetus; Indomethacin; Macaca; Macaca fasc | 1982 |
Effect of indomethacin and prostaglandin F2 alpha on parturition in swine.
Topics: Animals; Corpus Luteum; Female; Fetal Death; Indomethacin; Labor, Obstetric; Pregnancy; Progesterone | 1981 |
Oligohydramnion, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy.
Topics: Adult; Amniotic Fluid; Female; Fetal Death; Humans; Indomethacin; Infant Mortality; Infant, Newborn; | 1980 |
The effects of repeated doses of indomethacin on fetal rabbit mortality and on the patency of the ductus arteriosus.
Topics: Animals; Constriction, Pathologic; Ductus Arteriosus; Female; Fetal Death; Fetus; Indomethacin; Mate | 1980 |
Prevention of human recombinant interleukin-1 beta (rhIL-1 beta) embryolethality with progesterone or indomethacin.
Topics: Adjuvants, Immunologic; Animals; Cytosine; Drug Interactions; Female; Fetal Death; Indomethacin; Int | 1995 |
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide.
Topics: Abortion, Spontaneous; Animals; Bacterial Infections; Decidua; Dose-Response Relationship, Drug; Enz | 1995 |
Persistent anuria, neonatal death, and renal microcystic lesions after prenatal exposure to indomethacin.
Topics: Adult; Anuria; Dilatation, Pathologic; Female; Fetal Death; Humans; Immunohistochemistry; Indomethac | 1994 |
Indomethacin in severe twin-to-twin transfusion syndrome.
Topics: Adult; Female; Fetal Death; Fetofetal Transfusion; Humans; Indomethacin; Infant Mortality; Infant, N | 1993 |
In utero congestive heart failure due to maternal indomethacin treatment for polyhydramnios and premature labour in a fetus with antenatal closure of the foramen ovale.
Topics: Adult; Autopsy; Female; Fetal Death; Heart Failure; Heart Septum; Humans; Indomethacin; Obstetric La | 1996 |
Bacterial lipopolysaccharide-mediated murine fetal death: the role of interleukin-1.
Topics: Animals; Antibodies; Dinoprostone; Female; Fetal Death; Indomethacin; Interleukin-1; Lipopolysacchar | 1997 |
Hysterotomy and selective delivery of an intrauterine dead fetus to prevent intrauterine death or brain damage of the surviving fetus in monochorionic twin pregnancy.
Topics: Adult; Delivery, Obstetric; Diseases in Twins; Female; Fetal Death; Gestational Age; Humans; Indomet | 1997 |
The effects of cervical application of inhibitors of inducible nitric oxide synthase, cyclooxygenase-1, and cyclooxygenase-2 on delivery in rats.
Topics: Administration, Topical; Animals; Cervical Ripening; Cervix Uteri; Cyclooxygenase Inhibitors; Delive | 2001 |
Perinatal use of indomethacin.
Topics: Animals; Female; Fetal Death; Humans; Indomethacin; Obstetric Labor, Premature; Pregnancy; Rats | 1977 |
Failure of in vitro-expanded hyperimmune cytotoxic T lymphocytes to affect survival of mouse embryos in vivo.
Topics: Animals; Cells, Cultured; Embryo, Mammalian; Female; Fetal Death; Graft Survival; Immune Tolerance; | 1991 |
Indomethacin therapy in the treatment of symptomatic polyhydramnios.
Topics: Adult; Amniocentesis; Diuresis; Female; Fetal Death; Fetal Monitoring; Fetus; Gestational Age; Human | 1990 |
Treatment with prostaglandins reduces the antifertility effect of indomethacin in rabbits.
Topics: Animals; Embryo Implantation; Female; Fertility; Fetal Death; Indomethacin; Pregnancy; Progesterone; | 1986 |
Effect of indomethacin on alcohol-induced morphological anomalies in mice.
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Ethanol; Female; Fertility; Fetal Death; Indometh | 1987 |
Premature closure of the ductus arteriosus causing intra-uterine death. A case report.
Topics: Adult; Ductus Arteriosus; Edema; Female; Fetal Death; Humans; Indomethacin; Obstetric Labor, Prematu | 1986 |
Letter: Inhibitors of prostaglandin synthesis and fetal development.
Topics: Animals; Cell Differentiation; Female; Fetal Death; Fetus; Gestational Age; Indomethacin; Mice; Preg | 1974 |
Inhibitors of prostaglandin synthesis during pregnancy. 1. Embryopathic activity of indomethacin in mice.
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetal Death; Fetal Diseases; Fetus; Gestational Age; I | 1974 |
Inhibitors of prostaglandin synthesis during pregnancy. 2. The effects of indomethacin in pregnant rats.
Topics: Abnormalities, Drug-Induced; Animals; Female; Fetal Death; Fetal Diseases; Fetus; Growth; Indomethac | 1974 |
Aspirin and indomethacin prolong parturition in rats: evidence that prostaglandins contribute to expulsion of fetus.
Topics: Administration, Oral; Animals; Aspirin; Biological Assay; Chickens; Chromatography, Thin Layer; Fema | 1972 |
Delay of parturition in the rat by anti-inflammatory agents which inhibit the biosynthesis of prostaglandins.
Topics: Acetates; Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Cortisone; Depression, C | 1972 |
Relationship between endotoxin-induced abortion and the synthesis of prostaglandin F.
Topics: Abortion, Induced; Animals; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Endotoxin | 1972 |
The role of prostaglandin in endotoxin-induced abortion and fetal death.
Topics: Abortion, Induced; Animals; Cyproheptadine; Depression, Chemical; Endotoxins; Female; Fetal Death; H | 1973 |